TriCelX files first cell therapy IND for CTE and launches DoD collaboration

By AI, Created 4:10 AM UTC, May 25, 2026, /AGP/ – TriCelX has launched XytriX as a Department of Defense collaboration and filed a Phase 1/2 IND for chronic traumatic encephalopathy on May 15, 2026. The company says the filing is the first cell therapy IND in CTE and includes concurrent requests for RMAT and Breakthrough Therapy designations.

Why it matters: - TriCelX is trying to create a federal pathway for a cell therapy aimed at blast-related traumatic brain injury and chronic traumatic encephalopathy in service members and veterans. - The filing could shape how the Department of Defense handles investigational treatments for blast exposure and CTE under the Blast Overpressure Safety Act. - The program also seeks to accelerate development through concurrent RMAT and Breakthrough Therapy designation requests.

What happened: - TriCelX launched XytriX™ as a Department of Defense collaboration tied to the duty framework in DoD Instruction 6200.02 and the Blast Overpressure Safety Act of December 2024. - The company filed a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration for XytriX™ in chronic traumatic encephalopathy on May 15, 2026. - TriCelX says the filing is the first cell therapy in CTE and the first to request RMAT designation and Breakthrough Therapy Designation at the same time. - The company positioned the program to serve active-duty service members and veterans affected by blast traumatic brain injury.

The details: - The XytriX™ CTE trial is an open-label, three-cohort dose-escalation Phase 1/2 study. - The study evaluates intravenously administered allogeneic human umbilical cord-derived mesenchymal stem cell therapy in adults with biomarker-confirmed Traumatic Encephalopathy Syndrome under Katz 2021 research criteria. - The trial uses a plasma multiomics biomarker framework with Simoa HD-X measurements of p-tau217, neurofilament light chain, and glial fibrillary acidic protein at baseline and follow-up time points. - The program is anchored to the DIAGNOSE CTE comparator framework and the Federal Interagency Traumatic Brain Injury Research data commons. - XytriX™ is manufactured at TriCelX’s FDA-registered cGMP facility in Frisco, Texas. - The same drug substance is also in Phase 1/2 development for knee osteoarthritis under a separate IND filed March 30, 2026. - TriCelX says the parallel osteoarthritis program adds active-duty-relevant safety data to the broader XytriX™ regulatory package. - The company cites more than two decades of mesenchymal stem cell safety data, including a 2013 study by Wang et al. and a 2024 systematic review by Saboori et al. covering 11 trials and 402 patients. - TriCelX says those studies reported neurological improvement and no serious adverse events. - The company also says XytriX™ may support additional future INDs in Alzheimer’s disease, Crohn’s disease, multiple sclerosis, spinal cord injury, degenerative disc disease, and radiological/nuclear combined-injury countermeasures.

Between the lines: - TriCelX is framing the effort as a federal mandate execution, not a traditional commercial partnership pitch. - The company is building around government programs and data systems, including USAMMDA, BARDA, NIH/NINDS, CDMRP, NICoE, AFRRI, USSOCOM, and the Veterans Health Administration. - The regulatory strategy leans on biomarker-based endpoints and the RMAT/accelerated approval pathway rather than the FDA Animal Rule. - That approach reflects the company’s view that cell therapies need a different approval architecture for medical countermeasures and blast-related brain injury. - The company’s medical rationale centers on chronic microglial neuroinflammation and GSK-3β-mediated tau hyperphosphorylation in blast-exposed patients.

What’s next: - TriCelX says it is negotiating a Cooperative Research and Development Agreement with USAMMDA’s Warfighter Readiness, Performance and Brain Health program office. - The company expects the National Intrepid Center of Excellence to serve as a Phase 2/3 clinical infrastructure partner. - TriCelX also points to Expanded Access protocols under DoDI 6200.02 and 21 CFR Part 312 Subpart I as the bridge from early clinical development to care access. - The company is seeking federal engagement for a broader combined-injury medical countermeasure strategy.

The bottom line: - TriCelX is positioning XytriX™ as both a first-in-indication cell therapy and a federally aligned treatment pathway for blast-related CTE.